knitr::opts_chunk$set(echo = TRUE)
##Cost utility analysis of Rivaroxaban in the prevention of VTE reoccurrence versus standard or care with warfarin: A markov Model-Based Simulation
##remove any variables in R's Memory
rm(list = ls())
##Install packages for Markov Model
library("heemod")
library("diagram")
library("flexsurv")
library("mstate")
library("hesim")
library("BCEA")
library("ggplot2")
library("scales")
library("data.table")
# Load Markov model function for rivaroxaban and warfarin
source("function_markov.R")
##Model Input
n.t   <- 12                                       # time horizon, 12 cycles
#The model states:  Index Event = IE; No Event = NE; VTE Recurrence = VR; Major Bleed = MB; Clinically relevant Non-Major Bleed = NMB; Off Treatment = OT
v.n   <- c("NE", "VR", "MB", "NMB", "OT")         # Model states
n.s   <- length(v.n)                              # The number of health states
v.M_1 <- c(1, 0, 0, 0, 0)                         # Everyone begins in index event
d.c   <- d.e <- 0.05                              # Equal discounting of costs and QALYs by 5%
v.Trt <- c("Rivaroxaban")                         # Store the strategy names
##Cost utility analysis of Rivaroxaban in the prevention of VTE reoccurrence versus standard or care with warfarin: A markov Model-Based Simulation
##remove any variables in R's Memory
rm(list = ls())
##Install packages for Markov Model
library("heemod")
library("diagram")
library("flexsurv")
library("mstate")
library("hesim")
library("BCEA")
library("ggplot2")
library("scales")
library("data.table")
# Load Markov model function for rivaroxaban and warfarin
source("function_markov.R")
##Model Input
n.t   <- 12                                       # time horizon, 12 cycles
d.c   <- d.e <- 0.05                              # Equal discounting of costs and QALYs by 5%
#The model states:  Index Event = IE; No Event = NE; VTE Recurrence = VR; Major Bleed = MB; Clinically relevant Non-Major Bleed = NMB; Off Treatment = OT
v.n   <- c("NE", "VR", "MB", "NMB", "OT")         # Model states
v.M_1 <- c(1, 0, 0, 0, 0)                         # Everyone begins in index event
#v.Trt <- c("Rivaroxaban")                         # Store the strategy names
###Rivaroxaban###
##Health States
#Transition probabilities (per cycle):
pr.ne_ne   <- 0.856               # probability from no event to no event
pr.ne_vr   <- 0                   # probability from no event to VTE recurrence
pr.ne_mb   <- 0.019               # probability from no event to  major bleed
pr.ne_nmb  <- 0.125               # probability from no event to CRNMB
pr.nmb_ot  <- 0.019               # probability from CNMB to come off treatment
pr.nmb_nmb <- 1 - pr.nmb_ot
pr.mb_ot   <- 1                   # probability from MB to come off treatment
pr.mb_mb   <- 1 - pr.mb_ot
#List of parameter values
l.probr <- list(pr.ne_ne=pr.ne_ne,
pr.ne_vr=pr.ne_vr,
pr.ne_mb=pr.ne_mb,
pr.ne_nmb=pr.ne_nmb,
pr.nmb_ot=pr.nmb_ot,
pr.mb_ot=pr.mb_ot)
##Cost
c.ne      <- 142                #Cost for staying healthy in rivaroxaban arm
c.vr      <- 215                #Cost for VTE recurrence in Rivaroxaban arm ($73)
c.mb      <- 490                #Cost for major bleed in Rivaroxaban arm ($348)
c.nmb     <- 304                #Cost for CRNMB in Rivaroxaban arm ($162)
c.ot      <- 0                  #Cost of off treatment
##Utility Values
u.ne    <- 0.825               #Utility of No Event
u.vr    <- 0.76                #Utility of recurrence
u.mb    <- 0.65                #Utility of major bleed
u.nmb   <- 0.61                #Utility of CRNMB
u.ot    <- 0.59                #Utility of off treatment
##Vectors for cost and utility values
v.cost <- c(c.ne, c.vr, c.mb, c.nmb, c.ot)
v.util <- c(u.ne, u.vr, u.mb, u.nmb, u.ot)
##Cost utility analysis of Rivaroxaban in the prevention of VTE reoccurrence versus standard or care with warfarin: A markov Model-Based Simulation
##remove any variables in R's Memory
rm(list = ls())
##Install packages for Markov Model
library("heemod")
library("diagram")
library("flexsurv")
library("mstate")
library("hesim")
library("BCEA")
library("ggplot2")
library("scales")
library("data.table")
# Load Markov model function for rivaroxaban and warfarin
source("function_markov.R")
##Model Input
n.t   <- 12                                       # time horizon, 12 cycles
d.c   <- d.e <- 0.05                              # Equal discounting of costs and QALYs by 5%
#The model states:  Index Event = IE; No Event = NE; VTE Recurrence = VR; Major Bleed = MB; Clinically relevant Non-Major Bleed = NMB; Off Treatment = OT
v.n   <- c("NE", "VR", "MB", "NMB", "OT")         # Model states
v.M_1 <- c(1, 0, 0, 0, 0)                         # Everyone begins in index event
###Rivaroxaban###
##Health States
#Transition probabilities (per cycle):
pr.ne_ne   <- 0.856               # probability from no event to no event
pr.ne_vr   <- 0                   # probability from no event to VTE recurrence
pr.ne_mb   <- 0.019               # probability from no event to  major bleed
pr.ne_nmb  <- 0.125               # probability from no event to CRNMB
pr.nmb_ot  <- 0.019               # probability from CNMB to come off treatment
pr.nmb_nmb <- 1 - pr.nmb_ot
pr.mb_ot   <- 1                   # probability from MB to come off treatment
pr.mb_mb   <- 1 - pr.mb_ot
#List of parameter values
l.probr <- list(pr.ne_ne=pr.ne_ne,
pr.ne_vr=pr.ne_vr,
pr.ne_mb=pr.ne_mb,
pr.ne_nmb=pr.ne_nmb,
pr.nmb_ot=pr.nmb_ot,
pr.mb_ot=pr.mb_ot)
##Cost
c.ne      <- 142                #Cost for staying healthy in rivaroxaban arm
c.vr      <- 215                #Cost for VTE recurrence in Rivaroxaban arm ($73)
c.mb      <- 490                #Cost for major bleed in Rivaroxaban arm ($348)
c.nmb     <- 304                #Cost for CRNMB in Rivaroxaban arm ($162)
c.ot      <- 0                  #Cost of off treatment
##Utility Values
u.ne    <- 0.825               #Utility of No Event
u.vr    <- 0.76                #Utility of recurrence
u.mb    <- 0.65                #Utility of major bleed
u.nmb   <- 0.61                #Utility of CRNMB
u.ot    <- 0.59                #Utility of off treatment
##Vectors for cost and utility values
v.cost <- c(c.ne, c.vr, c.mb, c.nmb, c.ot)
v.util <- c(u.ne, u.vr, u.mb, u.nmb, u.ot)
##Run the Simulation
sim_markov_riv <- Markov(n.t, d.c, d.e, v.n, v.cost, v.util, v.M_1, l.probr)
##Cost utility analysis of Rivaroxaban in the prevention of VTE reoccurrence versus standard or care with warfarin: A markov Model-Based Simulation
##remove any variables in R's Memory
rm(list = ls())
##Install packages for Markov Model
library("heemod")
library("diagram")
library("flexsurv")
library("mstate")
library("hesim")
library("BCEA")
library("ggplot2")
library("scales")
library("data.table")
# Load Markov model function for rivaroxaban and warfarin
source("function_markov.R")
##Model Input
n.t   <- 12                                       # time horizon, 12 cycles
d.c   <- d.e <- 0.05                              # Equal discounting of costs and QALYs by 5%
#The model states:  Index Event = IE; No Event = NE; VTE Recurrence = VR; Major Bleed = MB; Clinically relevant Non-Major Bleed = NMB; Off Treatment = OT
v.n   <- c("NE", "VR", "MB", "NMB", "OT")         # Model states
v.M_1 <- c(1, 0, 0, 0, 0)                         # Everyone begins in index event
###Rivaroxaban###
##Health States
#Transition probabilities (per cycle):
pr.ne_ne   <- 0.856               # probability from no event to no event
pr.ne_vr   <- 0                   # probability from no event to VTE recurrence
pr.ne_mb   <- 0.019               # probability from no event to  major bleed
pr.ne_nmb  <- 0.125               # probability from no event to CRNMB
pr.nmb_ot  <- 0.019               # probability from CNMB to come off treatment
pr.nmb_nmb <- 1 - pr.nmb_ot
pr.mb_ot   <- 1                   # probability from MB to come off treatment
pr.mb_mb   <- 1 - pr.mb_ot
#List of parameter values
l.probr <- list(pr.ne_ne=pr.ne_ne,
pr.ne_vr=pr.ne_vr,
pr.ne_mb=pr.ne_mb,
pr.ne_nmb=pr.ne_nmb,
pr.nmb_ot=pr.nmb_ot,
pr.mb_ot=pr.mb_ot)
##Cost
c.ne      <- 142                #Cost for staying healthy in rivaroxaban arm
c.vr      <- 215                #Cost for VTE recurrence in Rivaroxaban arm ($73)
c.mb      <- 490                #Cost for major bleed in Rivaroxaban arm ($348)
c.nmb     <- 304                #Cost for CRNMB in Rivaroxaban arm ($162)
c.ot      <- 0                  #Cost of off treatment
##Utility Values
u.ne    <- 0.825               #Utility of No Event
u.vr    <- 0.76                #Utility of recurrence
u.mb    <- 0.65                #Utility of major bleed
u.nmb   <- 0.61                #Utility of CRNMB
u.ot    <- 0.59                #Utility of off treatment
##Vectors for cost and utility values
v.cost <- c(c.ne, c.vr, c.mb, c.nmb, c.ot)
v.util <- c(u.ne, u.vr, u.mb, u.nmb, u.ot)
##Run the Simulation
sim_markov_riv <- Markov(n.t, d.c, d.e, v.n, v.cost, v.util, v.M_1, l.probr)
sim_markov_riv
##Cost utility analysis of Rivaroxaban in the prevention of VTE reoccurrence versus standard or care with warfarin: A markov Model-Based Simulation
##remove any variables in R's Memory
rm(list = ls())
##Install packages for Markov Model
library("heemod")
library("diagram")
library("flexsurv")
library("mstate")
library("hesim")
library("BCEA")
library("ggplot2")
library("scales")
library("data.table")
# Load Markov model function for rivaroxaban and warfarin
source("function_markov.R")
##Model Input
n.t   <- 12                                       # time horizon, 12 cycles
d.c   <- d.e <- 0.05                              # Equal discounting of costs and QALYs by 5%
#The model states:  Index Event = IE; No Event = NE; VTE Recurrence = VR; Major Bleed = MB; Clinically relevant Non-Major Bleed = NMB; Off Treatment = OT
v.n   <- c("NE", "VR", "MB", "NMB", "OT")         # Model states
v.M_1 <- c(1, 0, 0, 0, 0)                         # Everyone begins in index event
###Rivaroxaban###
##Health States
#Transition probabilities (per cycle):
pr.ne_ne   <- 0.856               # probability from no event to no event
pr.ne_vr   <- 0                   # probability from no event to VTE recurrence
pr.ne_mb   <- 0.019               # probability from no event to  major bleed
pr.ne_nmb  <- 0.125               # probability from no event to CRNMB
pr.nmb_ot  <- 0.019               # probability from CNMB to come off treatment
pr.nmb_nmb <- 1 - pr.nmb_ot
pr.mb_ot   <- 1                   # probability from MB to come off treatment
pr.mb_mb   <- 1 - pr.mb_ot
#List of parameter values
l.probr <- list(pr.ne_ne=pr.ne_ne,
pr.ne_vr=pr.ne_vr,
pr.ne_mb=pr.ne_mb,
pr.ne_nmb=pr.ne_nmb,
pr.nmb_ot=pr.nmb_ot,
pr.mb_ot=pr.mb_ot)
##Cost
c.ne      <- 142                #Cost for staying healthy in rivaroxaban arm
c.vr      <- 215                #Cost for VTE recurrence in Rivaroxaban arm ($73)
c.mb      <- 490                #Cost for major bleed in Rivaroxaban arm ($348)
c.nmb     <- 304                #Cost for CRNMB in Rivaroxaban arm ($162)
c.ot      <- 0                  #Cost of off treatment
##Utility Values
u.ne    <- 0.825               #Utility of No Event
u.vr    <- 0.76                #Utility of recurrence
u.mb    <- 0.65                #Utility of major bleed
u.nmb   <- 0.61                #Utility of CRNMB
u.ot    <- 0.59                #Utility of off treatment
##Vectors for cost and utility values
v.cost <- c(c.ne, c.vr, c.mb, c.nmb, c.ot)
v.util <- c(u.ne, u.vr, u.mb, u.nmb, u.ot)
##Run the Simulation
sim_markov_riv <- Markov(n.t, d.c, d.e, v.n, v.cost, v.util, v.M_1, l.probr)
sim_markov_riv
